To the Editor: Dyck's article (July 29 issue) concluded that“Prednisone is generally reported to be beneficial in acute inflammatory demyelinating polyradiculoneuropathies, such as the Guillain–Barré syndrome, although there is one report to the contrary.“1 Before this statement can be used to justify the use of prednisone treatment in acute demyelinating polyneuropathy, a more complete analysis of the available data is needed. There have been many uncontrolled trials of steroid therapy that have given contradictory results.2 Two controlled trials have come to differing conclusions. The United States study,3 which excluded patients requiring ventilatory support, found that the time to. . . No extract is available for articles shorter than 400 words.
ASJC Scopus subject areas